Li Bao

7PUBLICATIONS
6CO-AUTHORS
PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Toxicology (incl. clinical toxicology)Gene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 14, 2026
Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Shan Gao, Junling Zhuang, Aijun Liu

|Apr 15, 2025
Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.

Ya-Lan Zhou, Jin-Qiao Zhang, Wei Wang

|Mar 30, 2023
Risk-benefit ratio of percutaneous kyphoplasty and percutaneous vertebroplasty in patients with newly diagnosed multiple myeloma with vertebral fracture: a single-center retrospective study.

Qiu-Qing Xiang, Bin Chu, Min-Qiu Lu

|Oct 22, 2022
Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China.

Li Bao, Ai-Jun Liu, Bin Chu

|Mar 30, 2022
Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.

Yu-Tong Wang, Li Bao, Bin Chu

|Nov 04, 2020
Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients.

Li Bao, Yutong Wang, Minqiu Lu

Pageof 2

Frequent Collaborators

2 joint publications

Wenming Chen

1 joint publications

Yu-Jun Dong

1 joint publications

Huixing Zhou

1 joint publications

Zhongjun Xia